TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06729450: Efficacy and Tolerability of DispersinB Acne Cleanser in the Treatment of Mild to Moderate Acne Vulgaris

Sponsor: Kane Biotech Inc · Phase: PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 24 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$3,663,600

Rescue Site Savings

+$2,425,200

Unlock Full NCT06729450 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06729450 Rescue Dossier →